24,347 Shares in argenex SE $ARGX Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. bought a new stake in argenex SE (NASDAQ:ARGX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 24,347 shares of the company’s stock, valued at approximately $20,475,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Diversified Trust Co. acquired a new stake in shares of argenex in the fourth quarter valued at $621,000. Fulton Bank N.A. acquired a new position in argenex during the 4th quarter worth about $212,000. Wealth Enhancement Advisory Services LLC lifted its stake in argenex by 52.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 563 shares of the company’s stock worth $452,000 after acquiring an additional 193 shares in the last quarter. Harbor Investment Advisory LLC boosted its holdings in argenex by 13.9% during the 4th quarter. Harbor Investment Advisory LLC now owns 131 shares of the company’s stock valued at $110,000 after acquiring an additional 16 shares during the period. Finally, Aventura Private Wealth LLC acquired a new position in argenex in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. Morgan Stanley lifted their price objective on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. DZ Bank raised shares of argenex to a “strong-buy” rating in a research note on Friday, December 19th. Stifel Nicolaus increased their target price on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $999.22.

argenex Trading Down 0.6%

Shares of ARGX stock opened at $692.83 on Friday. The company has a market cap of $42.87 billion, a P/E ratio of 35.49, a PEG ratio of 1.15 and a beta of 0.38. The firm has a fifty day moving average price of $783.22 and a 200 day moving average price of $814.12. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%. On average, equities analysts forecast that argenex SE will post 3.13 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.